Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504947 | 1.00 | HPGD (0.58) | HPGDGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9372814 | 1.00 | HPGD (0.58) | HPGDGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3183667 | 0.89 | ACE (0.55) | HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6039762 | 0.89 | ACE (0.55) | HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3183657 | 0.89 | ACE (0.55) | HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6786426 | 0.89 | ACE (0.55) | HPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4296465 | 0.88 | HPGD (0.57) | HPGDGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5743912 | 0.87 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL5743909 | 0.87 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL11209691 | 0.85 | DPP4 (0.55) | HPGDALDH1A1RAB9AL3MBTL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133004-A1 | Process for producing new oxazepine derivatives | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | claimed |
| EP-1219611-A1 | NOVEL PROCESSES FOR PREPARING OXAZEPINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | claimed |
| US-20020133004-A1 | Process for producing new oxazepine derivatives | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | disclosed |
| US-20020133004-A1 | Process for producing new oxazepine derivatives | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219611-A1 | NOVEL PROCESSES FOR PREPARING OXAZEPINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1219611-A1 | NOVEL PROCESSES FOR PREPARING OXAZEPINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133004-A1 | Process for producing new oxazepine derivatives | KMO, CYP4B1, GRIN2B | HPGD 610/4885GAA 2540/4885SMN1; SMN2 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.